The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 18, 2022
Filed:
Mar. 03, 2020
Agenus Inc., Lexington, MA (US);
Memorial Sloan-kettering Cancer Center, New York, NY (US);
Ludwig Institute for Cancer Research Ltd., Zurich, CH;
Marc Van Dijk, Bosch en Duin, NL;
Ekaterina V. Breous-Nystrom, Basel, CH;
Volker Seibert, Lörrach, DE;
Gerd Ritter, New York, NY (US);
David Schaer, Mamaroneck, NY (US);
Daniel Hirschhorn-Cymerman, New York, NY (US);
Taha Merghoub, Jersey City, NJ (US);
Hao Tang, Lexington, MA (US);
David A. Savitsky, Boxford, MA (US);
Jeremy Waight, Everett, MA (US);
Nicholas S. Wilson, San Carlos, CA (US);
Agenus Inc., Lexington, MA (US);
Memorial Sloan-Kettering Cancer Center, New York, NY (US);
Ludwig Institute for Cancer Research Ltd., Zurich, CH;
Abstract
The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.